JCJoon Hyouk Choi

Joon Hyouk Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joon Hyouk Choi has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Automated Extraction of Pulsatile Stiffness and Wall Asymmetry from Aortic M-Mode Ultrasound Images

    by Cheong-Ah Lee, Dong-Guk Paeng, Joon Hyouk Choi

    Conventional ultrasound-based assessment of aortic stiffness relies on two-point distension metrics using maximum and minimum vessel diameters within a cardiac cycle, which may not fully reflect time-resolved aortic wall dynamics. This retrospective pilot study investigated the feasibility and clinical relevance of a time-series-based stiffness parameter, termed pulsatile stiffness-β, derived from automated segmentation of archived aortic M-mode ultrasound images. Seventy-nine cases with available aortic M-mode images were analyzed. Automated image processing was used to segment the anterior and posterior aortic walls and reconstruct diameter waveforms. Conventional stiffness-β, pulsatile stiffness-β, and wall asymmetry-related parameters were calculated and compared with demographic, tonometry-derived, hemodynamic, coronary burden, cardiovascular risk, and echocardiographic variables. Conventional and pulsatile stiffness-β were strongly correlated and showed directionally consistent associations with established vascular functional parameters, including systolic blood pressure, pulse pressure, augmentation pressure, age, and cardiovascular risk burden. Pulsatile stiffness-β demonstrated association patterns broadly comparable to conventional stiffness-β, suggesting its role as a waveform-informed extension rather than a superior alternative. Wall asymmetry-related parameters were associated with the Syntax score. Automated analysis of archived aortic M-mode images may provide feasible time-resolved vascular biomarkers for stiffness and wall motion assessment.

  • Open Access

    Effectiveness and Safety of Biodegradable Polymer-Coated Everolimus-Eluting Stent in Multivessel Coronary Artery Disease in Routine Clinical Practice: A Korean Multicenter, Prospective, and Observational Study

    by Soohyung Park, Woohyeun Kim, Seung-Woon Rha, Byoung Geol Choi, Joo-Yong Hahn, Sang-Ho Park, Han Cheol Lee, Jang Hyun Cho, Jung Min Bong, Byung-Hee Hwang, et al.

    Park S, et al. J Korean Med Sci. 2026 Mar;41:e85. https://doi.org/10.3346/jkms.2026.41.e85


  • Open Access

    Optimal duration of medical therapy for patients with acute myocardial infarction

    by Ki Yung Boo, Seung-Jae Joo, Jae-Geun Lee, Joon-Hyouk Choi, Song-Yi Kim, Geum Ko, Hae Eun Yun, Myung Ho Jeong, on behalf of the KAMIR-NIH investigators

    Optimal medical therapy, including Beta-blockers (BB), inhibitors of the renin-angiotensin system (RAS), and statins, is recommended for patients with acute myocardial infarction (AMI) in the absence of contraindications. However, the optimal duration of these medications has not been clearly established in clinical studies. This observational study aimed to investigate the period during which these medications are associated with improved clinical outcomes. Among patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH), in-hospital survivors were selected. In a Cox-proportional hazard analysis of 12,200 patients, BB (hazard ratio [HR] = 0.73; 95% confidence interval [CI] = 0.57–0.95; P = .019), RAS inhibitors (HR 0.70; 95% CI = 0.55–0.89; P = .004), and statins at discharge (HR = 0.65; 95% CI = 0.48–0.87; P = .004) were all associated with lower 1-year cardiac mortality. At 1-year, 10,613 patients without all-cause death, myocardial infarction, revascularization, or re-hospitalization due to heart failure were selected for further analysis. RAS inhibitors (HR = 0.53; 95% CI = 0.37–0.76; P = .001) and statins (HR = 0.30; 95% CI = 0.14–0.61; P = .001) prescribed at 1-year were associated with lower 2-year cardiac mortality, whereas BB were not (HR = 0.79; 95% CI = 0.51–1.23; P = .23). However, none of these medications prescribed at 2-years were associated with reduced 3-year cardiac mortality among the 9232 patients who remained event-free until then. RAS inhibitors and statins were associated with reduced cardiac mortality for up to 2-years, and BB for up to 1-year after the initial attack. The effectiveness of these medications beyond these periods remains questionable.


  • Open Access

    A Novel Method for Angiographic Contrast-Based Diagnosis of Stenosis in Coronary Artery Disease: In Vivo and In Vitro Analyses

    by Woongbin Kang, Cheong-Ah Lee, Gwansuk Kang, Dong-Guk Paeng, Joonhyouk Choi

    Background: The existing diagnostic methods for coronary artery disease (CAD), such as coronary angiography and fractional flow reserve (FFR), have limitations regarding their invasiveness, cost, and discomfort. We explored a novel diagnostic approach, coronary contrast intensity analysis (CCIA), and conducted a comparative analysis between it and FFR. Methods: We used an in vitro coronary-circulation-mimicking system with nine stenosis models representing various stenosis lengths (6, 18, and 30 mm) and degrees (30%, 50%, and 70%). The angiographic brightness values were analyzed for CCIA. The in vivo experiments included 15 patients with a normal sinus rhythm. Coronary angiography was performed, and arterial movement was tracked, enabling CCIA derivation. The CCIA values were compared with the FFR (n = 15) and instantaneous wave-free ratio (iFR; n = 11) measurements. Results: In vitro FFR showed a consistent trend related to the length and severity of stenosis. The CCIA was related to stenosis but had a weaker correlation with length, except for with 70% stenosis (6 mm: 0.82 ± 0.007, 0.68 ± 0.007, 0.61 ± 0.004; 18 mm: 0.78 ± 0.052, 0.69 ± 0.025, 0.44 ± 0.016; 30 mm: 0.80 ± 0.018, 0.64 ± 0.006, 0.40 ± 0.026 at 30%, 50%, and 70%, respectively). In vitro CCIA and FFR were significantly correlated (R = 0.9442, p < 0.01). The in vivo analysis revealed significant correlations between CCIA and FFR (R = 0.5775, p < 0.05) and the iFR (n = 11, R = 0.7578, p < 0.01). Conclusions: CCIA is a promising alternative for diagnosing stenosis in patients with CAD. The initial in vitro validation and in vivo confirmation in patients demonstrate the feasibility of applying CCIA during coronary angiography. Further clinical studies are warranted to fully evaluate the diagnostic accuracy and potential impact of CCIA on CAD management.


  • Open Access

    Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction

    by Seung-Jae Joo, Song-Yi Kim, Jae-Geun Lee, Jong Wook Beom, Joon-Hyouk Choi, Hyeung Keun Park, Ki Yung Boo, Chang-Hwan Yoon, Jung-Hee Lee, Jei Keon Chae, et al.

    In the era of the initial optimal interventional and medical therapy for acute myocardial infarction (AMI), a number of patients with mildly reduced left ventricular ejection fraction (EF) (41%–49%) have been increasing. This observational study aimed to investigate the association between the medical therapy with oral beta-blockers or inhibitors of renin-angiotensin system (RAS) and 2-year clinical outcomes in patients with mildly reduced EF after AMI. Among patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health, propensity-score matched patients who survived the initial attack and had mildly reduced EF were selected according to beta-blocker or RAS inhibitor therapy at discharge. Beta-blocker therapy at discharge was associated with lower 2-year major adverse cardiac events which was a composite of cardiac death, myocardial infarction, revascularization and re-hospitalization due to heart failure (8.7 vs 12.8/100 patient-years; hazard ratio [HR] 0.68; 95% confidence interval [CI] 0.50–0.93; P = .015), and no significant interaction between EF ≤ 45% and > 45% was observed (P interaction = 0.354). This association was mainly driven by lower myocardial infarction in patients with beta-blockers (HR 0.50; 95% CI 0.26–0.95; P = .035). Inhibitors of RAS at discharge were associated with lower re-hospitalization due to heart failure (1.8 vs 3.5/100 patient-years; HR 0.53; 95% CI 0.33–0.86; P = .010) without a significant interaction between EF ≤ 45% and > 45% (P interaction = 0.333). In patients with mildly reduced EF after AMI, the medical therapy with beta-blockers or RAS inhibitors at discharge was associated with better 2-year clinical outcomes.


  • Open Access

    Comparison of Factors Associated With Direct Versus Transferred-in Admission to Government-Designated Regional Centers Between Acute Ischemic Stroke and Myocardial Infarction in Korea

    by Dae-Hyun Kim, Seok-Joo Moon, Juneyoung Lee, Jae-Kwan Cha, Moo Hyun Kim, Jong-Sung Park, Byeolnim Ban, Jihoon Kang, Beom Joon Kim, Won-Seok Kim, et al.

    Kim DH, et al. J Korean Med Sci. 2022 Oct;37(42):e305. https://doi.org/10.3346/jkms.2022.37.e305


  • Open Access

    Validation of Biomarker-Based ABCD Score in Atrial Fibrillation Patients with a Non-Gender CHA2DS2-VASc Score 0–1: A Korean Multi-Center Cohort

    by Moonki Jung, Kyeongmin Byeon, Ki-Woon Kang, Yae Min Park, You Mi Hwang, Sung Ho Lee, Eun-Sun Jin, Seung-Young Roh, Jin Seok Kim, Jinhee Ahn, et al.

    Jung M, et al. Yonsei Med J. 2022 Oct;63(10):892-901. https://doi.org/10.3349/ymj.2022.0157


  • Open Access

    Evaluation of Efficacy and Safety of Paclitaxel and Cilostazol Dual Drug-eluting Coronary Stents

    by Jong Wook Beom, Chang Hun Kum, Seung Jae Joo, Joon Hyouk Choi, Jae-Geun Lee, Sung-Yun Lee, Yun-Hyeong Cho, Song-Yi Kim

    Beom JW, et al. J Cardiovasc Interv. 2022 Jul;1(3):124-133. https://doi.org/10.54912/jci.2022.0002

  • Open Access

    A successfully treated case of primary purulent pericarditis complicated by cardiac tamponade and pneumopericardium

    by Jong Wook Beom, Yeekyoung Ko, Ki Yung Boo, Jae-Geun Lee, Joon Hyouk Choi, Seung-Jae Joo, Ji Hwan Moon, Su Wan Kim, Song-Yi Kim

    A successfully treated case of primary purulent pericarditis complicated by cardiac tamponade and pneumopericardium Acute pericarditis is caused by various factors, but purulent pericarditis is rare. Primary purulent pericarditis in immunocompetent hosts is very rare in the modern antibiotics era. We report a successfully treated case of primary purulent pericarditis complicated with cardiac tamponade and pneumopericardium in an immunocompetent host. A 69-year-old female was referred from another hospital because of pleuritic chest pain with a large amount of pericardial effusion. She was diagnosed with acute pericarditis accompanied by cardiac tamponade. We performed emergency pericardiocentesis, with drainage of 360 ml of bloody pericardial fluid. The culture grew Streptococcus anginosus, confirming the diagnosis of acute purulent pericarditis. We performed pericardiostomy because cardiomegaly and pneumopericardium were aggravated after removal of the pericardial drainage catheter. The patient received antibiotics for a total of 23 days intravenously and was discharged with oral antibiotic therapy. Purulent pericarditis is one of the rare forms of pericarditis and is lifethreatening. A multimodality approach is required for proper diagnosis and treatment of this disease.


  • Open Access

    Contemporary Status of Acute Myocardial Infarction in Korean Patients: Korean Registry of Acute Myocardial Infarction for Regional Cardiocerebrovascular Centers

    by Rock Bum Kim, Jin Yong Hwang, Hyun Woong Park, Ae-Young Her, Jang Hoon Lee, Moo Hyun Kim, Chang Hwan Yoon, Jae Young Cho, Sung-Il Woo, Yongcheol Kim, et al.

    Background: This study aimed to present the development process and characteristics of the Korean Registry of Acute Myocardial Infarction for Regional Cardiocerebrovascular Centers (KRAMI-RCC). Methods: We developed KRAMI-RCC, a web-based registry for patients with AMI. Patients from 14 RCCs were registered for more than three years from July 2016. It includes an automatic error-checking system, and user training and on-site monitoring are performed to manage data quality. Results: A total of 11,700 AMI patients were registered in KRAMI-RCC over three years (73.9% men). The proportions of patients with ST-elevation and non-ST-elevation myocardial infarction at discharge were 43.4% and 56.6%, respectively. Of the total three-year patients, 5.6% died in the hospital, and 4.4% died 12 months after discharge. The case fatality within 12 months was 9.7%. Pre-hospital care data showed delayed arrival time after onset of symptoms (median 153 min) and low transportation rate by public ambulance (25.2%). Post-hospital care data showed lower participation rate in the second rehabilitation program (16.8%). Conclusions: The recently developed KRAMI-RCC registry has been more focused on pre-hospital and post-hospital data, which will be helpful in understanding the current state of AMI disease management and in making policy decisions to reduce case fatality in Korea.